Clinical Pharmacokinetics of Clonidine

Clinical Pharmacokinetics

Volumn 14, Issue 5, 1988, Pages 287-310

  Lowenthal, D T ^a,b   Matzek, K M ^a,b   MacGregor, T R ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONIDINE;

HUMAN; REVIEW;

CLONIDINE; HUMAN;

EID: 0024009653     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-198814050-00002     Document Type: Review

References (129)

1. Hypertension associated with clonidine
2. Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects
3. New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man
4. Pharmacokinetics and pharmacodynamics of transdermally administered clonidine
5. New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man
6. Development of a RIA for clonidine and its comparison with the reference methods
7. A newly developed precise and sensitive radioimmunoassay for clonidine
8. Clonidine poisoning: a complex problem
9. Drug therapy in renal failure: dosing guidelines for adults
10. Pharmacokinetics of transdermal drug delivery
11. Nomogram for drug dosage adjustment in patients with renal failure
12. Effect of clonidine on regional blood flow and its use in the treatment of hypertension
13. Transdermal administration of clonidine for treatment of mild-to-moderate essential hypertension
14. Catapres transdermal therapeutic system (TTS) for long-term treatment of hypertension
15. Hemodynamic and cardiac effects of clonidine
16. Alpha and beta-adrenoceptor changes in patients on maintenance hemodialysis
17. Transdermal administration of clonidine: a new approach to antihypertensive therapy
18. Oral clonidine loading combined with transdermal clonidine in essential hypertension
19. Effects of acute and chronic treatment with clonidine
20. Pharmacokinetics of drug permeation through human skin
21. Design of transdermal therapeutic systems
22. Determination of submicrogram quantities of clonidine in biological fluids
23. Reduced renovascular resistance by clonidine
24. Metabolischer abbau von clonidin
25. Applications of stable isotope labelling in studies of the pharmacokinetics and metabolism of clonidine
26. Pharmacokinetics and concentration effect relationships of intravenous and oral clonidine
27. Clinical pharmacology and pharmacokinetics of clonidine
28. Relationship between plasma concentrations of clonidine and mean arterial pressure during an accidental clonidine overdose
29. Current concepts in the evaluation and treatment of patients with mild to moderate hypertension
30. Determination of clonidine in human plasma by glass capillary/gas chromatography with electron-capture detection
31. Transcutaneous clonidine in the treatment of adolescent hypertension
32. Radioimmunoassay for clonidine in human plasma and urine using a solid phase second antibody separation
33. 14C-clonidine in normal and uraemic patients
34. Mass transport phenomena and models: theoretical concepts
35. Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients
36. Clonidine kinetics in man: evidence for dose dependency and changed pharmacokinetics during chronic therapy
37. Relationship between the cardiovascular effects and steady-state kinetics of clonidine in hypertension
38. Initial therapy for hypertension
39. Bullous dermatosis of hemodialysis
40. Transdermal clonidine in elderly patients with mild hypertension: effects on blood pressure and plasma catecholamines
41. Effect of clonidine therapy on renal hemodynamics in renal transplant hypertension
42. Limb blood flow: rest and heavy exercise in sitting and supine positions in man
43. Transdermal clonidine application: long-term results in essential hypertension
44. Diabetes and hypertension: clonidine monotherapy
45. Clonidine in patients with diabetes and mild hypertension
46. Pharmacokinetics interpretation of the plasma levels of clonidine following transdermal delivery
47. The effect of insulin induced hypoglycemia on plasma renin activity and urinary catecholamines before and following clonidine in man
48. Studies on the possible contribution of a peripheral presynaptic action of clonidine and dopamine to their vascular effects under in vivo conditions
49. Pharmacokinetics of clonidine during pregnancy and nursing
50. Systematische Untersuchungen zur proteinbindung biologisch wirksamer Substanzen
51. Plasma clonidine concentration and pharmacologic effect
52. Absorption of clonidine from a transdermal therapeutic system when applied to different body sites
53. Absorption and excretion of clonidine following application of Catapres-TTS to different skin sites
54. Clonidine in depressed kidney function
55. Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome
56. Clonidine hydrochloride
57. Synthesis of clonidine and 1,3-dimethyl-clonidine labelled at specific positions with deuterium and carbon-13
58. Clinical efficacy and pharmacokinetics of clonidine in hemodialysis and renal insufficiency
59. Clonidine in the central nervous system: site and mechanism of hypotensive action
60. Clonidine and the kidney
61. Effects of transdermal clonidine in young and elderly patients with mild hypertension: evaluation by 3 non invasive methods of blood pressure measurement
62. Bioavailability and clinical effects of three brands of clonidine: the relationship between plasma level and effect
63. Diurnal variations in thermoregulatory functions
64. Pharmacokinetics and side-effects of clonidine
65. Autonomic insufficiency in uremia as a cause of hemodialysis induced hypotension
66. Transdermal clonidine therapy in elderly mild hypertensives: effects on blood pressure, plasma norepinephrine and fasting plasma glucose
67. Central alpha-adrenergic systems as targets for hypotensive drugs
68. Circulation studies with 2-(2, 6-di-chlorophenylamino)-2-imidazoline hydrochloride
69. Low dose oral and transdermal application of clonidine in mild hypertension: hemodynamic and biochemical correlates
70. Transdermal clonidine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy
71. Relationship of immunoassayable clonidine plasma levels to its pharmacologic action in clinical and experimental hypertension
72. Pharmacokinetics of clonidine
73. Pharmacokinetics and pharmacodynamics of clonidine in varying states of renal function
74. The use of transdermal clonidine in the hypertensive patient with chronic renal failure
75. Pharmacodynamics and pharmacokinetics of oral and trans-dermal clonidine in chronic renal insufficiency
76. Efficacy of clonidine, a transdermal therapeutic system: the international clinical trial experience
77. Pharmacokinetics and pharmacodynamics of transdermal clonidine in renal insufficiency
78. Pharmacokinetics of transdermally delivered clonidine
79. Pharmacokinetics or oral sustained release clonidine in humans
80. Regional hemodynamic effects of clonidine in congestive heart failure
81. Plasma clonidine in relation to blood pressure catecholamines, and renin activity during long-term treatment of hypertension
82. Clinical experience with clonidine TTS
83. Dose-response of clonidine on plasma catecholamines in the hypernoradrenergic state associated with vasodilator β-blocker therapy
84. Preliminary evaluation of transdermal clonidine administration in hypertensive patients receiving a diuretic
85. Intravenous clonidine in hypertensive patients
86. Circulatory effects at rest and exercise of clonidine, an imidazoline derivative with hypotensive properties
87. Plasma and urine by combined gas chromatography/mass spectrometry with ammonia chemical ionization
88. Role of renin and aldosterone suppression in the antihypertensive mechanism of clonidine
89. Hemodialysis hypotension is not the result of uremic peripheral autonomic neuropathy
90. Antihypertensive effect of clonidine
91. Pharmacodynamic effects of a new antihypertensive drug, Catapres (ST-155)
92. The transition from oral to transdermal clonidine in varying degrees of renal function
93. Pharmacology of clonidine
94. Evidence for a renal α-adrenergic receptor inhibiting renin release
95. Baroreflex sensitivity in patients on long term hemodialysis
96. A double-blind placebo-controlled trial of transdermal clonidine in mild hypertension
97. Transdermal clonidine in mild hypertension: a randomized, double-blind, placebo-controlled trial
98. Transdermal clonidine for hypertensive patients
99. The central hypotensive effect of clonidine
100. Mechanism of autonomic dysfunction in uremia: evidence for reduced end organ response to norepinephrine
101. Uremic dermatitis
102. Percutaneous absorption in the aged
103. Human cardiovascular adjustments to exercise and thermal stress
104. Antihypertensive drugs and the drug therapy of hypertension
105. Pharmacodynamics of oral and transdermal clonidine in varying degrees of renal function
106. Transdermal clonidine therapy in hypertensive patients
107. Transdermal administration of clonidine in hypertensive patients
108. Cutaneous manifestations of hyperlipidemia and uraemia
109. Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route
110. Transdermal therapeutic systems
111. Clonidine rate-controlled system: technology and kinetics
112. Arcadian rhythm in sweating and cutaneous blood flow
113. Effects of clonidine and chlorthalidone on blood pressure and glucose tolerance in hypertensive patients
114. Clonidine, a centrally acting sympathetic inhibitor, as mono-therapy for mild to moderate hypertension
115. Plasma clonidine levels in hypertension
116. The use of trans-cutaneous clonidine hydrochloride in patients with diabetes mellitus and mild hypertension
117. Discontinuation syndrome following cessation of treatment with clonidine and other antihypertensive agents
118. Transdermal antihypertensive therapy: clinical and metabolic considerations
119. Renin and aldosterone suppression in the antihypertensive action of clonidine
120. Clinical experience with rate-controlled delivery of antihypertensive therapy by a transdermal system
121. Transdermal administration of clonidine for treatment of high blood pressure
122. Clinical effectiveness of the transdermal route of antihypertensive treatment
123. Transdermal continuous antihypertensive therapy
124. Pharmacokinetic and concentration effect relationships of clonidine in essential hypertension
125. The therapeutic uses of clonidine